~~<i id='7C3A3C599F'><strike id='7C3A3C599F'><tt id='7C3A3C599F'><pre id='7C3A3C599F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

author：entertainment 2025-09-06 01:59:51 - browse：17

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： FDA official pushes for dedicated emerging pathogens team

focus

leisure time

hotspot

leisure time

explore

ThepharmagiantAbbViespentnearly$4milliononlobbyinginthefirstthreemonthsof2022—nearlyamilliondollarsm

WSS

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

A new House health package & hospitals’ new site

How to fix cancer clinical trials' diversity problem

'Make People Better': The CRISPR babies story you probably don't know

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Elizabeth Warren probes abortion access

Wikipedia

Wikipedia

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Medical leaders decry Supreme Court decision on affirmative action

Amazon on where the company's health care bets are headed next

As demand for Covid shots wanes, Moderna seeks its next success

Covid hospitalizations on the rise, Humana says

As demand for Covid shots wanes, Moderna seeks its next success

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Body of missing toddler recovered in Delaware River days after flood: Police

focus

Artificial intelligence advances fuel industry trying to preserve loved ones after death

NIH nominee Bertagnolli will get October confirmation hearing

Caitlin Bernard's story shows physicians can't shy from advocacy

Will.i.am, Britney Spears release new single, 'Mind Your Business'

How to fix cancer clinical trials' diversity problem

Organ transplantation is at a crossroads. Major reform is needed

leisure time

hotspot

leisure time

explore